Life Couriers' New Chapter: PE and a Veteran CEO Target Global Pharma's Edge

MUNICH, Germany – August 17, 2026 – The world of highly specialized healthcare logistics saw a significant strategic realignment today as Life Couriers, a global leader in time-critical medical transport, announced the completion of its acquisition by New York-based private equity firm JLL Partners. The deal, which places a high-value asset into a portfolio known for cultivating market leaders, is coupled with a leadership change: Edward DeMartini, an industry veteran with over two decades of experience, has been appointed Chief Executive Officer.

This move is more than a simple change in ownership; it represents a calculated injection of capital and expertise into a sector where the margin for error is zero and the human impact is immeasurable. As therapies become more personalized and time-sensitive, the supply chain that delivers them is evolving into one of the most critical components of modern healthcare. With this acquisition, JLL Partners is making a clear statement about the future value of mastering medicine's last mile.

A Strategic Bet on Precision Logistics

JLL Partners' acquisition of Life Couriers is a textbook example of a private equity firm targeting a high-growth, resilient niche. The firm, which recently closed a $1.4 billion fund, has a long history of investing in the healthcare sector, with a portfolio that includes companies in life sciences, medical devices, and outsourced healthcare services. The move into time-critical logistics aligns perfectly with its thesis of investing in durable, secular trends that are less correlated with broad economic cycles.

The market Life Couriers operates in is not just growing; it is booming. The broader healthcare logistics market is on a trajectory to surpass $480 billion by 2035. More specifically, the niche segments where Life Couriers excels are seeing explosive demand. The market for radiopharmaceutical logistics—transporting radioactive isotopes with extremely short half-lives for cancer diagnosis and treatment—is projected to more than double, reaching nearly $16 billion by 2034. Similarly, the Direct-to-Patient (DTP) model, which delivers clinical trial materials and specialized medicines directly to patient homes, is forecast to grow at a CAGR of 9.6%, transforming how care is delivered.

“We are pleased to close the acquisition of Life Couriers at a time where we are seeing heightened demand for crucial radiopharmaceutical and medical logistics solutions,” said Daniel Di Piazza, Managing Director at JLL Partners. This statement underscores the strategic calculation: investing in the essential infrastructure that underpins the next generation of medicine, from advanced cell and gene therapies to personalized oncology. By acquiring a platform with a global footprint and deep expertise, JLL is not just buying a company; it is securing a strategic position in the future of patient care.

New Leadership to Scale a Global Platform

To steer this newly capitalized platform, JLL has brought in a seasoned navigator of global supply chains. New CEO Edward DeMartini's resume reads like a tour of the world’s most complex logistics operations. His most recent role was as CEO of The Quick Group of Companies, a Kuehne + Nagel subsidiary specializing in time-critical transport. His career also includes senior leadership roles at Kuehne + Nagel and DHL, where he was instrumental in building “white-glove global transportation solutions for the healthcare industry.”

DeMartini’s appointment signals an intense focus on operational excellence and scalable growth. His track record demonstrates a capacity for leading global teams and developing bespoke solutions for the most demanding supply chain challenges. “It’s an honor to join and lead Life Couriers, a company that delivers for patients during life’s most critical moments,” DeMartini stated. “Together, we will look to extend our reach into new geographic markets while reinforcing our position as the most trusted leader for radiopharmaceutical and time-critical healthcare deliveries globally.”

DeMartini takes the helm from Stefan Glebke, who will transition to a strategic advisor role for the board. Glebke’s tenure was transformative, overseeing the integration of multiple acquisitions—including Aktiv-Trans in Germany and On Time Delivery in the US—and rebranding the collection of specialized operators into the cohesive Life Couriers global platform. He successfully positioned the business for this next stage of growth, creating the attractive, integrated asset that caught JLL’s eye.

Accelerating the Patient-Centric Supply Chain

The infusion of JLL’s capital is set to act as a powerful accelerant for an expansion strategy that is already in motion. Life Couriers has been aggressively building out its capabilities in its most critical segments. In radiopharma, the 2024 acquisition of Aktiv-Trans solidified its market leadership in Europe, a move followed by the launch of a specialized radiopharma service in the UK in 2025. This focus is critical in a field where isotopes like Fluorine-18, a key component in PET scans, have a half-life of only 110 minutes, demanding a logistics network that operates with surgical precision.

Simultaneously, the company has been rapidly expanding its DTP network, a service that improves life for patients by removing the burden of travel for clinical trials or ongoing treatment. Recent depot openings in Exeter and Gosport in the UK are part of a broader strategy to increase warehousing capacity and strengthen operational capabilities, ensuring that medical supplies, from trial medications to chronic care treatments, arrive safely and on time at a patient's front door.

Under JLL’s ownership and DeMartini’s leadership, this expansion is expected to go global, with a focus on developing direct infrastructure in Asia and South America. The investment will enable further technological enhancements, building on the company’s real-time tracking and customs clearance expertise to create a truly seamless and resilient global network. For a company built on a “zero-failure mentality,” this new chapter is about scaling that reliability across the globe, ensuring that no matter where a patient is, the life-saving therapies they depend on can reach them.